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Aim To assess the effectiveness and outcome of repeated 
percutaneous transhepatic balloon dilatation combined 
with targeted intramucosal corticosteroid injection in pa-
tients with benign biliary stricture.
Methods This single-center pilot study, conducted be-
tween February 2014 and June 2016, involved five patients 
with benign biliary stricture (4 men and 1 woman, mean 
age 58.2 years). The study included only patients in whom 
previous surgical or/and non-surgical treatments failed or 
could not be performed due to patients’ medical history 
and local status.
Results We successfully developed an alternative treat-
ment for patients with benign biliary stricture and per-
formed it without side effects. There were no major 
complications, and the only one minor complication 
was cholangitis. In the median follow-up period of 30.24 
months (range 14.5 to 44.6 months), no re-occlusion was 
detected. The disease-free survival, calculated after exclud-
ing the first patient (who died of heart attack), was 34.175 
months.
Conclusion Percutaneous transhepatic corticosteroid in-
jection combined with balloon dilatation could provide 
an alternative method for the treatment of benign biliary 
strictures that is effective in the long term and results in 
positive outcomes.
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Benign biliary stricture is a rare condition mostly caused 
by operative trauma (1,2). The majority (80%) of surgical 
trauma is inflicted during cholecystectomy with incidence 
rates of 0.2-0.3% after open cholecystectomy and 0.4%-
0.6% after laparoscopic cholecystectomy (3). The rising 
number of laparoscopic cholecystectomies has increased 
the occurrence of benign biliary stricture. The second most 
common cause is fibrosis at the site of surgical anastomo-
sis (1). Risk factors for stricture include anastomosis leak-
age, small stoma size, ischemia, and the stent placement at 
the stoma. Other causes are chronic pancreatitis, scleros-
ing cholangitis, cholelithiasis, impacted stones, sphinctero-
tomy, and biliary tract infection (3,4).
The highest long-term stricture resolution rate was 
achieved by surgery (84%), followed by multiple plas-
tic stent insertions (79%), and percutaneous transhepat-
ic treatment with covered self-expandable metal stents 
(SEMS) (75%), without significant differences between the 
treatments (5). None of these therapies offer a definitive, 
reliable long-term solution for this disease, and therapy is 
still determined on a case-by-case basis. In addition, the 
long-term patency of these methods is unacceptable – 
particularly when considering the longer life expectancy 
of patients with this benign disease. All this indicates that 
benign biliary structures require new treatment strategies.
The pathophysiologic mechanisms involved in benign 
biliary stricture development are inflammatory responses 
with collagen deposition and fibrosis formation. Therefore, 
a viable treatment option could be pharmacological cor-
ticosteroid administration, especially as this method has 
been successfully used by plastic surgeons in scar thera-
py for almost 50 years (6). Since no data are available on 
percutaneous application at biliary strictures, we aimed 
to assess the effectiveness and outcome of repeated tran-
shepatic balloon dilatation and corticosteroid injection in 
benign biliary strictures.
MATeriAL And MeTHOdS
This single-center pilot study, conducted between Febru-
ary 2014 and June 2016, involved five patients (4 men, 1 
woman) with mean age of 58.2 years (range 32-74). The 
strict inclusion criteria: diagnosis of benign biliary stricture, 
contraindication or lack of feasibility of surgical and non-
surgical (endoscopy) treatments due to general or local 
status, resulted in a super-selected patient group.
In three patients, benign biliary stricture occurred due to 
chronic pancreatitis and in two patients due to bile duct 
injury following laparoscopic cholecystectomy (Table 1). 
No surgical and non-surgical corrections of the anastomot-
ic strictures had been permanently successful.
All five patients underwent the same procedure complying 
with the ethical standards of Hungarian Medical Research 
Council (062350/2015/OTIG) and the Helsinki Declaration.
We began each treatment with the patient in the supine 
position. The primary puncture was performed in the 9th-
10th intercostal space on the patient’s right side. Once the 
Chiba needle (Cook Medical, Bloomington, IN, USA) was in 
the bile duct, as confirmed with cholangiography, a 0.018-
inch wire (Cook Medical) was advanced and the needle was 
removed. A percutaneous access set (Cook Medical) with 
two sheaths and a metal cannula was used to introduce a 
cannula accepting a larger wire suitable for the planned in-
tervention. After the coaxial tip was inserted into the bile 
duct using the 0.018-inch wire, the two inner components 
were removed, leaving the outer 4French (F) sheath be-
hind. Cholangiography was performed to determine the 
TAbLe 1. demographic and clinical data of patients with benign biliary stricture who underwent repeated percutaneous transhe-
patic balloon dilatation combined with targeted intramucosal corticosteroid injection
Patient no. Age Sex etiology








1 57 M chronic pancreatitis II Frey’s procedure yes* yes
2 69 F laparoscopic 
cholecystectomy
III hepatico-jejunostomy no† yes
3 32 M laparoscopic 
cholecystectomy
II hepatico-jejunostomy no‡ no
4 74 M chronic pancreatitis III Frey’s procedure yes§ yes
5 59 M chronic pancreatitis III Frey’s procedure no yes
*Failed stent implantation.
†Failed balloon dilatations.
‡insufficient and narrow anastomosis.
§Without long-term success.
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obstruction level. A 4F biliary manipulation catheter (Cook 
Medical) was used to cross the obstructing lesion. The 
0.018-inch wire was left in place to preserve the route for 
security reasons. By means of a 0.038-inch wire, a 7F Flexor 
access with curved tip configuration (Cook Medical) was in-
serted into the stricture. After removing the inner stiffener, 
a flexible 0.7 mm diameter needle (Endoflex Gmbh, Voerde, 
Germany) was introduced. Then 40 mg triamcinolone (Ken-
alog, KRKA d.d., Novo Mesto, Slovenia) was injected spatially 
into the stricture and equally distributed by manipulating 
the flexible tip seeking catheter and a transluminal needle 
under continuous fluoroscopic control. After the injection, 
balloon dilatation (14 mm in diameter) with 5-bar pressure 
was repeated three times. Finally, a 10.2F drain (Cook Medi-
cal) was left behind bridging the stricture (Figure 1, A-D).
This procedure was performed two more times with a one-
month recovery period between treatments. The drains 
were removed two weeks after the third treatment. The fol-
low up consisted of blood tests and ultrasound examina-
Figure 1. Technical steps of repeated percutaneous transhepatic balloon dilatation combined with targeted intramucosal corti-
costeroid injection. (A) Percutaneous transhepatic cholangiography. (B) injection of 40 mg triamcinolone intramucosally into the 
stricture spatially with a flexible tip seeking catheter and a transluminal needle under fluoroscopic control. (C) balloon dilatation (ř14 
mm, 5 bar). (D) drainage (ř10.2 F).
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tions every six months in the first year and blood tests and 
MR scans once each following year.
reSuLTS
All patients tolerated their procedures well, and all 15 treat-
ments were successful, with no technical failures or Ken-
alog-related side effects. Clinical success was achieved in 
all patients without major complications, such as perfora-
tion (bile leak), hemobilia, sepsis, pneumothorax, or death. 
Only one minor complication, cholangitis, occurred in the 
fourth patient due to drain occlusion, which was treated 
with simple drain lavage and conservative antibiotic thera-
py. Four patients had stone extraction (two percutaneously 
assisted during the last treatment, two after the treatments 
with rendezvous technique). One patient required an ad-
ditional treatment one year after the procedure, when an 
elevated obstructive parameter (alkaline phosphatase: 468 
U/L) indicated the presence of a non-symptomatic biliary 
stone. After this treatment, the patient developed cholan-
gitis, but no new biliary stone presented during the follow 
up. Two patients complained of intermittent mild pain for 
one year after the procedure.
Each intervention lasted on average 30-45 minutes. The 
inpatient length of stay averaged three days, and the pa-
tients were discharged home without any complaints. The 
control fluoroscopic images completed after the repeated 
procedures showed radical extension at each time point 
compared with the first dilatation (Figure 2, A-C).
The final follow-up visits took place in February 2018, 
when clinical examinations, blood tests, and ultrasound 
were performed. The median follow-up period was 30.24 
months (range 14.5-44.6 months). The first patient died of 
a treatment-unrelated cause (heart attack) 14.5 months af-
ter the end of treatment and he was excluded from the 
disease-free calculation (Table 2). None of the patients had 
re-occlusion. After the end of the procedures, the patients 
gained from 3 to 25 kg (mean 7.6 kg). None of the patients 
reported pain or other biliary stricture related symptoms. 
The last ultrasound examinations showed no significant 
obstruction in any patient. The intrahepatic bile ducts and 
extrahepatic duct were in the reference range (Table 2). 
The disease-free survival was 34.175 months.
diSCuSSiOn
This study showed that our novel treatment could be a 
viable alternative solution for benign biliary stricture. Bile 
duct decompression can be achieved by endoscopy, per-
cutaneous transhepatic intervention, or surgery. However, 
none of these approaches is generally accepted or yields a 
good long-term outcome, and the treatment is usually de-
termined on a case-by-case basis (5).
Since non-surgical and surgical procedures have similar 
long-term patency rates, the selection of the treatment 
method varies based on several aspects, including the 
practitioner’s expertise. Furthermore, it is almost impossible 
to compare these methods due to unavailability of relevant 
long-term follow-up data (2-4). A multicenter, open-label, 
parallel, randomized clinical trial showed that covered SEMS 
had the highest resolution rate of 92.6% (7). Plastic stents 
had the highest resolution rate of 84%, which is unaccept-
able considering the benign nature of the disease with long 
Figure 2. results of the dilatations with intramucosal corticosteroid administration. dilatation using ø14 mm balloon with 5 bar as 
the first (A), second (B), and third (C) treatment. The increasing maximal extension of the balloon shows the radical resolution of the 
stricture.
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life expectancy. Surgical approach aims to restore the bilio-
digestive continuity with hepaticojejunostomy or choledo-
choduodenostomy. Hepaticojejunostomy is the preferable 
solution in patients with benign biliary strictures, however 
these patients are often poor candidates for surgery due to 
severe co-existing medical conditions such as malnutrition, 
cirrhosis, and portal hypertension (2,3,8).
Whereas biliary stents were formerly primarily used for 
the palliative treatment of malignant biliary obstructions, 
TAbLe 2. Follow up results in patients with benign biliary stricture who underwent repeated percutaneous transhepatic balloon 














1  6 within reference 
range
high moderate intrahepatic bile 
duct dilatation, choledochus 
7 mm, no stone, no bile duct 
obstruction no
passed away from 
treatment non-
related causes after 
14.5 mo
14.5




moderate intrahepatic biliary 
duct dilatation, no stone, no 
sign for bile duct obstruction




no bile duct obstruction, no 
stone
no
completed the pilot 
study
44.6
12 within reference 
range
high no bile duct dilatation




no bile duct dilatation, no stone




moderate intrahepatic bile 
ducts, no stone




no bile duct dilatation, no stone




no intrahepatic bile duct 
dilatation
no
completed the pilot 
study
33.6




no bile duct dilatation, no stone




no bile duct dilatation, no stone




no bile duct dilatation
yes
non-symptomatic 
bile stone detected 
at 12 mo check-
up without bile 
duct obstruction. 
We successfully 
performed the 4th 
treatment and 
stone extraction, 









moderate bile duct dilation 
(better than previous), no stone
12 within reference 
range
high choledocholithiasis, moderate 
(ductus choledochus 12 mm) 
bile duct dilatation




moderate dilated bile ducts, no 
stone, aerobilia




no intrahepatic bile duct dilata-
tion, no stone




no bile duct dilatation, no stone
no
completed the pilot 
study
22.6




better dilatated bile duct dilata-
tion, no stone




moderate bile duct dilatation, 
no stone
*reference range: 0-5.5 umol/L.
†reference range: 80-300 u/L.
§ultrasound, Mri, CT.
RESEARCH ARTICLE402 Croat Med J. 2019;60:397-404
www.cmj.hr
over the decades they have started to be used to treat be-
nign biliary strictures. Single plastic stents – despite the 
easy applicability – have insufficiently small diameter and 
short patency. Therefore, there is a need for a more reli-
able multiple plastic stent, although even this type of stent 
would not be optimal because of short stent patency and 
the requisition of several endoscopic interventions. Other 
stents, such as cSEMS, have better stent-related conditions, 
but their reported long-term success rate is still 80%-90%. 
They also cause additional complications, like biliary infec-
tion, pancreatitis, bleeding, perforation, and early stent mi-
gration (4,7-10).
Another treatment, percutaneous biliary balloon dilata-
tion, is safe, useful, and inexpensive for the treatment of 
the benign anastomotic stricture of Roux-en-Y hepaticoje-
junostomy. Furthermore, percutaneous biliary balloon dila-
tation repeated three times consecutively with fixed time 
interval yields the desired patency rate (11).
None of the five patients in this study were suitable for sur-
gical treatment because of co-morbidities, intraoperative 
bleeding, or impracticability of the procedure. Due to their 
relatively young age (mean 58.2 years), they were also not 
suitable for biliary stent implantation since this procedure 
has unacceptable re-occlusion rate and inadequate long-
term outcomes. This is why we sought for an alternative 
therapy that would provide good long-term outcome and 
would not lead to undesired effects of stenting or surgery.
The pathophysiologic mechanism involved in benign bil-
iary stricture development is chronic inflammation accom-
panied with transmural fibrosis. The inflammatory process 
involving the massive aggregation of macrophages, syn-
thesizing and secreting polypeptide growth factors, could 
induce a marked fibroblast proliferation and excessive syn-
thesis and collagen deposition, resulting in a hypertrophic 
scar and consequential luminal obstruction (12). Mean-
while, plastic surgeons have used intralesional corticoster-
oid injection in scar therapy to decrease fibroblast prolif-
eration, collagen synthesis, glycosaminoglycan synthesis, 
and suppress pro-inflammatory mediators (12). However, 
the procedure has widely variable response rates and re-
currence rates (50%-100% and 9%-50%) (13), with a broad 
range of side effects, related only to prolonged usage due 
to the chemical nature of the drug, vehicle, and applica-
tion site (14).
On the other hand, submucosal approach does not 
cause side effects (15-17), except with large doses of 
steroids and aggressive therapy, when systemic effects of 
triamcinolone acetonide could provoke iatrogenic Cush-
ing syndrome due to adrenal insufficiency (18).
Several research groups have successfully applied corticos-
teroids to ameliorate different types of strictures. Ramage 
Jr et al (17) used them successfully in recalcitrant peptic 
esophageal stricture, which prolonged the need and the 
average time interval for repeat dilatations. Takahashi et al 
(19) showed profilactic endoscopic intramucosal steroid in-
jection therapy to be safe and effective in the treatment of 
a stenosis caused by a mucosal defect involving the entire 
circumference of the esophagus after endoscopic submu-
cosal dissection. Steroid injection could also be an effec-
tive and safe option in the treatment of therapy-resistant 
Lichen sclerosus (20) as well as of urethral strictures (12). 
However, in Crohn’s strictures intramural steroid injection 
could not be an option for adjuvant therapy (21). In 2010, 
an Italian randomized, double-blind, prospective pediatric 
study found that the endoscopic balloon dilatation with 
local corticosteroid injection successfully eliminated stric-
ture and reduced the re-dilatation and surgery rate (16). 
The study finally concluded that for inflammatory bowel 
disease-related strictures, endoscopic balloon dilation, 
with or without topical corticosteroid injection, was a safe 
and effective intervention in patients with short, bland, 
symptomatic strictures, and may obviate surgery.
Newer antifibrotic agents, like mitomycin C, were intro-
duced as a promising alternative to adjuvant treatment, 
but their efficacy has to be determined in further con-
trolled trials. The intralesional injection of triamcinolone 
and topical mitomycin C showed better results in the treat-
ment of benign esophageal strictures than balloon dilata-
tion alone (22). Based on histopathologic evaluation, both 
mytomicin-C and triamcinolone decreased the recurrence 
rates of urethral stricture formation in New Zealand rabbits, 
with no significant differences between the agents (23).
There are no available data about percutaneous transhe-
patic intramucosal corticosteroid administration for the 
treatment of benign bile duct strictures. However, in 2015, 
Franzini et al (24) reported a successful balloon dilation 
with cholangioscopy-guided steroid injection for benign 
biliary stricture in a patient who developed an anastomosis 
stricture after orthotopic liver transplantation. Accordingly, 
after two sessions of biliary balloon dilatation and cholan-
gioscopy-guided steroid injection, the patient recovered 
well without stent implantation and any adverse effects. Al 
Mahjoub et al (25) showed the clear superiority of the per-
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cutaneous approach compared with endoscopic interven-
tions in malignant perihilar obstructions, with lower com-
plication rate and less conversion. As our study showed, 
a definite advantage of the transhepatic approach is dis-
tinguished targeting and precise injection in the perihilar 
strictures. In special postsurgical cases, due to the modi-
fied anatomy, percutaneous transhepatic access may be 
the only possibility of stricture resolution.
Percutaneous transhepatic corticosteroid injection – as an 
alternative method – in combination with balloon dilata-
tion could provide effective and long-lasting results in the 
treatment of benign pancreatogenic strictures. This novel 
method can be easily performed, is inexpensive and safe, 
and provides good quality of life for the patients. Although 
the present results are promising, due to the small number 
of patients involved, they need to be confirmed by further 
clinical and animal studies.
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